$CAH

Hollar Jason M. sold $29.4M of CAH

Hollar Jason M. (Chief Executive Officer) sold 124,529 shares of CARDINAL HEALTH INC (CAH) at an average of $235.89 ($233.22–$237.88, $29.38M total) across 10 trades over 2026-08-18 to 2026-08-19.

Original reporting
SEC EDGAR · Hollar Jason M.
Published Aug 20, 2026, 11:33 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 11:38 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CAH
Bearish
high confidence
Mentioned
$CAH
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CAHBearishMed
01

Why it matters

The CEO's sizable share sale may influence investor sentiment and short‑term price action.

02

Market read

Insider sell by a top executive is a material event for a large‑cap health‑care distributor.

03

What to watch

No 10b5‑1 plan was in place, suggesting the trades were discretionary.

Relevance 7/10Novelty 8/10Timing: filed 2026‑08‑20, immediate market reaction expected

Background

Form 4 filing from SEC EDGAR discloses insider transactions.

Company-level read

Ticker impact

$CAHBearishHigh confidence
Context

CEO Jason Hollar sold 124,529 shares for $29.4M in a Form 4 filing.

Expected impact

Potential short-term dip of 2‑4% as market digests the sale.

Evidence & confidence

The sale size ($29.4M) is material for a large‑cap health‑care distributor and the insider is the CEO, making the signal noteworthy.

Market effects

May raise concerns for the health‑care distribution sector about executive confidence.

U.S. market could see modest sell pressure in related distribution stocks.

Limited to investors tracking U.S. health‑care distributors.

Counterpoint

The sale could be a routine portfolio rebalancing unrelated to company outlook.

Key entities

  • Jason M. Hollar

    Chief Executive Officer of Cardinal Health

  • Cardinal Health Inc.

    U.S. health‑care services and products distributor

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CAHMed

How CVS Deal Extension At Cardinal Health (CAH) Has Changed Its Investment Story

Cardinal Health (CAH) extended its pharmaceutical distribution agreement with CVS Health until 2032, reaffirming its fiscal 2027 non-GAAP EPS growth guidance of 13% to 15%. The extension secures a key partner, supporting Cardinal's strategy to shift toward higher-margin services. Analysts expect revenue of $297.6 billion and earnings of $3.0 billion by 2029. The company's upcoming Q1 results on November 5 will provide further insights.

$CAHHigh

Why is Cardinal Health stock rallying today?

Cardinal Health (CAH) stock rose 3.8% after extending its pharmaceutical distribution agreement with CVS Health (CVS) until 2032, removing investor uncertainty. The company reaffirmed its FY2027 EPS guidance of $12.40-$12.60. Today is the ex-dividend date for its quarterly dividend of $0.516 per share. The stock reached $235.95 intraday, with broader market gains providing a supportive backdrop.

$MCKMed

McKesson (MCK) and Cardinal Health Extend CVS Health Distributio

McKesson (MCK) and Cardinal Health renewed their pharmaceutical distribution agreements with CVS Health, extending contracts through June 2032. Both companies reaffirmed their fiscal 2027 earnings guidance. McKesson's stock is trading at $890.28, 6.8% above its GF Value of $833.49, with a GF Score of 86/100. Insider sales totaled $28.3 million over the past year, while 15 premium gurus hold MCK with a net positive addition.

$CAHMed

Why Is Cardinal Health and McKesson Stock Trading Higher Today - CVS Health (NYSE:CVS), McKesson (NYSE:MC

Cardinal Health (CAH) and McKesson (MCK) extended their distribution agreements with CVS Health (CVS) until 2032. Cardinal Health reaffirmed its 2027 adjusted earnings guidance of $12.40-$12.60 per share, while McKesson reiterated its 2027 outlook of $44.20-$45 per share. Both companies' stocks rose on the news, with McKesson up 4.28% and Cardinal Health up 2.94%.